News & Events

SoMS Seminar Series. Quantifying the benefits and risks of SGLT2 inhibitors in diabetes

School of Medical Sciences 2019 Seminar Series

Bruce Neal is Deputy Executive Director at The George Institute for Global Health in Australia, Professor of Medicine at UNSW Sydney and Professor of Clinical Epidemiology at Imperial College London. 

Bruce completed his medical training at Bristol University in the UK in 1990 and spent four years in clinical posts. Prior to taking up his position at the Institute in 1999 he worked as an epidemiologist at the Clinical Trials Research Unit in Auckland, New Zealand, where he completed his PhD in Medicine.

Bruce has a longstanding interest in the management of high blood pressure and diabetes and has held lead roles in several large-scale clinical trials.  He currently chairs the Steering Committees for the recently completed CANVAS and CANVAS-R trials of the SGLT2 inhibitor canagliflozin.  He is also a Steering Committee member for the soon to be reported CREDENCE trial assessing the effects of canagliflozin in patients with nephropathy.

More info: Professor Nigel Turner, Deputy Director of Research, SoMS UNSW Sydney

Event Date: 
Wednesday, 20 March 2019 - 4:00pm
Level 6 Kirby Seminar Room, Wallace Wurth Building
Booking deadline: